Related content

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

By Ruddy Kathryn   Desantis Stephen   Gelman Rebecca   Wu Alan   Punglia Rinaa   Mayer Erica   Tolaney Sara   Winer Eric   Partridge Ann   Burstein Harold  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 421-427

Springer Publishing Company

Access to resources Recommend Favorite

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients

By                      

Oncology Reports, Vol. 34, Iss. 4, 2015-01 ,pp. : 1883-1894

Spandidos Publications

Access to resources Recommend Favorite

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

By Siegelmann-Danieli Nava  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 505-510

Springer Publishing Company

Access to resources Recommend Favorite

CYP2D6 gene polymorphism in Caucasian smokers - lung cancer susceptibility and phenotype-genotype relationships

By Laforest L.   Wikman H.   Benhamou S.   Saarikoski S.T.   Bouchardy C.   Hirvonen A.   Dayer P.   Husgafvel-Pursiainen K.  

European Journal of Cancer, Vol. 36, Iss. 14, 2000-09 ,pp. : 1825-1832

Elsevier

Access to resources Recommend Favorite

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

By Azoulay Laurent  

Breast Cancer Research and Treatment, Vol. 126, Iss. 3, 2011-04 ,pp. : 695-703

Springer Publishing Company

Access to resources Recommend Favorite